KYNB

Conviction 18HealthcareScan · Mon, Aug 10, 2026

KYNB$7.08-2.61%

ResistanceSupportVol 14Insider buy

Vol MA14 5.48K

May 11May 28Jun 16Jul 6Jul 23Aug 10

KYNTRA BIO, INC.PHARMACEUTICAL PREPARATIONSwww.kyntrabio.com ↗

Price7.08

Change-2.61%

Gap-2.61%

Rel volume1.02×

Avg volume6.18K

Avg $ vol43.74K

SMA 207.06

SMA 507.06

SMA 200—

Price vs 50+0.30%

Price vs 200—

MA stack—

50/200 cross—

Supertrendup · 6.64

RSI (14)51

MACD hist0.01

MACD crossbull · 1d

Stoch %K / %D66 / 65

ADX (14)15

+DI / −DI19 / 17

RSI divergence—

MACD divergence—

ATR %+3.63%

ADR %3.02%

52w high9.50

52w low6.46

From 52w high-25.47%

Above 52w low+9.60%

New 52w highNo

SqueezeOn · 1d

Bollinger width10.93%

%B0.53

Donchian pos45.19%

Donchian high7.59

Donchian low6.66

AVWAP (52w high)7.44

vs AVWAP high-4.78%

AVWAP (52w low)7.13

vs AVWAP low-0.77%

OBV trendDown

Chaikin MF (20)-0.29

Today vs 20d1.02×

Avg vol (14d)5.47K

Avg vol (20d)6.18K

Avg $ vol (20d)43.74K

Market cap28.66M

RS 3m (vs SPY)-3.30%

RS 6m (vs SPY)-17.18%

RS line new highNo

Trend template—

Technical rank31.9

1 week+4.73%

1 month-6.90%

3 months+1.87%

6 months-13.87%

1 year—

YTD-25.47%

P/E0.16

P/B-0.65

P/S4.45

P/FCF-5.96

EPS45.37

Div yield—

ROE-418.81%

ROA167.34%

Debt/Eq-1.71

Current3.61

EV/EBITDA—

Gross margin—

Net margin—

Rev growth-78.26%

EPS growth485.57%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value66.66M

Revenue3.74M

Net income-15.2M

Gross profit—

Free cash flow-4.81M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out4.05M

Employees34

ListedFri, Nov 14, 2014

Free float3.88M

Float %95.7%

Short interest97.71K

Days to cover6.0d

Short volume20.5%

Squeeze score30 / 100

Next earningsThu, Aug 13, 2026 · after (3d)

EPS forecast−$3.18 · 3 est

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction18 / 100

Pattern quality—

Tech rank31.9 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance7.77

Support6.66

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in KYNB

All disclosures →

No recent disclosed trades by Congress in KYNB. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in KYNB · 2 buys · 2 sells

Insider	Side	Shares	Value	Traded	Filed
DeLucia David Chief Financial Officer · Common Stock · 2026-06-06	Tax	52	$349	2026-06-06	2026-06-09
Wettig Thane CEO · Common Stock · 2026-06-06	Tax	198	$1K	2026-06-06	2026-06-09
Wettig Thane CEO · Common Stock · 2026-06-06	Other	—	—	2026-06-06	2026-06-09
Wettig Thane CEO · Common Stock · 2026-05-14	Buy	2.8K	$20K	2026-05-14	2026-05-19
Wettig Thane CEO · Common Stock · 2026-05-14	Other	—	—	2026-05-14	2026-05-19
Wettig Thane CEO · Common Stock · 2026-05-14	Other	—	—	2026-05-14	2026-05-18
Wettig Thane CEO · Common Stock · 2026-05-14	Buy	2.8K	$20K	2026-05-14	2026-05-18

SEC filings

EDGAR filings in KYNB · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.